drugset / Trial / NCT07053358

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

NCT07053358 ↗

NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.

Timeline

Start
2025-07-02
Primary completion
2026-11-23
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LX111 Gene therapy (AAV / viral vector) — Intravitreal